Oxford Biomedica is Innurex (REG) produces limb function Provides an avulsion injury preclinical model ff
Oxford Biomedica, UK, (LSE - OXB), a leading gene therapy, announced today that preclinical nerve repair Innurex program presented by Dr. Nicholas Mazarakis, vice-president Companys neurobiology at the 7 th annual meeting of the American Society Gene Therapy, held in Minneapolis from June 2-6. The data, which will soon be submitted for publication in the peer-review show that Innurex is capable of restoring function of damaged components in a model of avulsion (stretch) injury.These results show that Innurex can clinical benefit in patients with nerve damage as a result of serious injury pull-stretching, a common result of accidents and motor sports. to repair the field of neurobiology of nerve a long-awaited target for the treatment of nerve injuries and spinal cord
injury has been. The goal is to make nerve cells to connect the bridge sites and the injury of the nerve fibers grow back and restore feature. Currently there are no effective treatments for nerve damage and spinal cord injuries.The new findings are the first Innurex with data from the Oxford BioMedica functional program to repair the nerves and nerve connections indicate that induced Innurex restore the important role of members who have a damaged nerve supply. The data were generated by an ongoing collaboration between Oxford Biomedica and Professor Malcolm Maden and Stephen McMahon at Kings College London. Alan Kingsman, Oxford BioMedicas CEO, said: Innurex goes from strength to strength.In December last year announced that Innurex shown to induce nerve regeneration in
vivo. We now know that new growth is significant because the injured limb to regain movement and sensation as a result of treatment with Innurex.Data presented at the 7th Annual Meeting of the American Society of Gene Therapy Notes 1. Oxford BioMedica Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company focused on developing new treatments based on genes with a focus on oncology and neurology. The Company
Pages: [1] 2 3